Soligenix, Inc. (SNGX) income statement
SNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$0.25−0.03 (-9.88%)
Close on Nov 18, 2026Market cap $5.50MP/E –Yield –
Soligenix, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -235.5%
Financial strength
- Current ratio
- 2.77
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 267.2%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.83
- Dividend yield
- –
See a number that looks wrong?